Xiangxue Pharmaceutical (300147 SHE) stock market data APIs
¥9.2468
-0.02(-0.2%)
as of January 16, 2026
Try our APIs with
free plan!
Xiangxue Pharmaceutical Financial Data Overview
Price chart is built with
Anychart
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sarsae, juice soda, soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides medical devices, which includes disposable stereoscopic fixation system for brain; medical orthopedic and cosmetic adhesives; medical tumor serosa sealing adhesives; medical anastomotic adhesives; medical aural and encephalic adhesives; medical obturation adhesives; medical adhesives; and endoscopic trocar. The company was founded in 1986 and is based in Guangzhou, China.
Prev. Close
9.2468
Open
9.2271
High
9.2702
Low
8.9953
52 wk Range
4.73-12.79
Market Cap
6 639 M
Shares Outstanding
661 M
Revenue
1 471 M
EPS
-0.1944
Beta
0.479
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xiangxue Pharmaceutical data using free add-ons & libraries
Get Xiangxue Pharmaceutical Fundamental Data
Xiangxue Pharmaceutical Fundamental data includes:
- Net Revenue: 1 471 M
- EBITDA: -121 976 264
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xiangxue Pharmaceutical News
New
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
Klisyri® is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-da...
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
Klisyri® is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-da...
Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy
Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S. BUFFALO, N.Y., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a gl...
Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy
Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S. BUFFALO, N.Y., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a gl...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
